Video

Dr. Winestone on Disparities with Diagnosis in Pediatric Leukemia

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Lena Winestone, MD, assistant professor, Department of Pediatrics, University of San Francisco Helen Diller Family Comprehensive Cancer Center, discusses disparities with diagnosis in pediatric leukemia.

Defining a delay in diagnosis of leukemia can be complex due to the ambiguity of some of the disease’s symptoms, Winestone explains, adding that a symptom such as fatigue could be attributed to leukemia or a range of other factors. Even after a blood test confirms the diagnosis, it is difficult to link a patient’s previous symptoms to the disease, Winestone continues.

However, there has not been evidence that a delay in diagnosis leads to problems in care for leukemia, Winestone adds. Rather than focusing on a potential delay in diagnosis, clinicians concentrate on defining how sick patients are at diagnosis and what effect the leukemia has had on the body’s other organs, Winestone explains. Identifying a patient’s acuity score can involve looking at their breathing, kidney function, liver function, and mental status, Winestone says.

Connecting a patient’s acuity score to a delay in diagnosis is still a complicated process, but Winestone notes that patients who are sicker and need to go to cancer intensive care unit at the time of diagnosis have worse outcomes. Higher rates of worse acuity scores at diagnosis have been documented in Black patients, and researchers are concerned that this is one of the factors attributing to worse outcomes among that population, Winestone concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity